New ValSource Rapid Response Team to address regulatory citations

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/mshch)
(Image: Getty/mshch)

Related tags: Management

The validation services company has created a Rapid Response Team to address pharmaceutical product regulatory and compliance citations.

The team is made up of ValSource’s “senior knowledge group​,” including consultants in microbiology, contamination prevention, process control, validation, data integrity, training, quality risk management, regulatory expectations, and quality system implementation.

"Time is critical when help is needed, especially when a regulatory response is needed in a defined period of time​,” ValSource Microbiology and Regulatory Consultant Dave Hussong told Outsourcing-Pharma.com.

Too often, finding a consultant who is available and has the needed skill set takes too much of that time as the response deadline approaches​.”

The team reviews technical and regulatory materials and presents findings to address regulatory concerns, microbiological procedures, data management, and acceptance criteria, according to the company.

The ability to assemble individuals with specific knowledge, skills and experience means that there is support focused on each specific issue among a range of problem areas​,” he added. “Multiple subject matter experts can come together and quickly resolve a client’s issues to meet the range of needs when the team divides this workload and can focus on concerns in the range of their expertise​.”

Related news

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Related suppliers

Follow us

Products

View more

Webinars